{"id":50410,"date":"2022-11-02T20:03:13","date_gmt":"2022-11-02T19:03:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/"},"modified":"2022-11-02T20:03:13","modified_gmt":"2022-11-02T19:03:13","slug":"early-is-good-raises-4-million-seed-round-from-social-capital","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/","title":{"rendered":"Early Is Good Raises $4 Million Seed Round from Social Capital"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Funds will be used to complete clinical trials for new early detection test for bladder cancer<\/i>\n<\/p>\n<p>INDIANAPOLIS&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/earlyisgood?src=hash\" target=\"_blank\" rel=\"noopener\">#earlyisgood<\/a>&#8211;Early is Good (EIG), a diagnostic solutions company focused on renal disease, announced it has closed a $4 million seed round from Social Capital, the Silicon Valley-based technology investment firm managed by Chamath Palihapitiya. EIG\u2019s mission is to enable the early, accurate, and widely accessible detection of renal system diseases, including bladder, kidney, and prostate cancers, by assessing specific biomarkers found in urine.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221102005821\/en\/1622879\/4\/eig_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221102005821\/en\/1622879\/21\/eig_logo.jpg\"><\/a><\/p>\n<p>\nThe funds will be used to complete clinical trials for EIG\u2019s first product, BCDx, a lab-developed test (LDT) for early bladder cancer detection. The BCDx test uses advanced nanotechnology to quantify a panel of biomarkers found in a patient\u2019s urine to diagnose bladder cancer and the stage of the disease.\n<\/p>\n<p>\nBladder cancer is among the most diagnosed cancers (#6 overall, #4 among men) in the U.S. In 2022, more than 81,000 people are expected to be diagnosed with bladder cancer, of which 17,000 are not expected to survive the disease. Once diagnosed, bladder cancer has a 50-80% recurrence rate, making it one of the most expensive cancers to treat over a patient&#8217;s lifetime.\n<\/p>\n<p>\n<b>Comparing BCDx to contemporary diagnostic methods<\/b>\n<\/p>\n<p>\nIn most cases, blood in the urine (hematuria) is the first sign of bladder cancer. Today, [if blood is present,] the diagnostic gold standard is to perform a cystoscopy (invasive) or cytology (under microscope). However, both techniques rely on the subjective observations of oncologists and pathologists, in addition to cystoscopies being invasive and uncomfortable, with potential complications including infection, bleeding, perforation, and urinary retention.\n<\/p>\n<p>\nThe BCDx assay is unique because it uses a single lab-developed test to evaluate a range of biomarkers from proteins, microRNAs, and mRNAs to long noncoding RNAs. The non-invasive technology does not require extraction or amplification and uses a hybrid dual read-out method to accurately quantify specific biomarkers.\n<\/p>\n<p>\nIn EIG\u2019s analytical validation study of BCDx, data demonstrates unprecedented attomolar sensitivity and specificity, with high PPV and NPV values for biomarkers that are present in picomolar concentrations and establishes a strong foundation for an effective, non-invasive, and robust diagnostic for the bladder cancer community.\n<\/p>\n<p>\n<b>Management Comments<\/b>\n<\/p>\n<p>\nEIG\u2019s founder and CEO, Thakshila Liyanage, Ph.D., said, \u201cDespite being one of the most common cancers in the U.S., we still rely on old techniques to diagnose bladder cancer. Our technology can distinguish healthy versus oncogenic phenotypes earlier and more specifically than a cystoscopy, while also having the benefit of being non-invasive and less reliant on inconvenient procedures and subjective analysis.\u201d\n<\/p>\n<p>\nSocial Capital partner, Jay Zaveri, said, \u201cEIG hopes to give millions of people access to accurate, convenient, and early diagnoses for renal diseases. With EIG\u2019s early breakthrough work around bladder cancer, they are developing a single lab-developed test, BCDx, which would enable patients to detect potential bladder cancer earlier and more conveniently than any other test currently available.\u201d\n<\/p>\n<p>\n<b>About Early is Good (EIG)<\/b>\n<\/p>\n<p>\nEarly is Good is based in Indianapolis, Indiana, with labs at the Indiana Biosciences Research Institute and the Indiana Center for Biomedical Innovation. EIG believes that earlier detection yields better outcomes and focuses on developing highly sensitive, accurate, and non-invasive diagnostic tests for early diagnosis and management care of cancer.\n<\/p>\n<p>\nTo learn more about Early is Good, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.earlyisgood.com&amp;esheet=52958991&amp;newsitemid=20221102005821&amp;lan=en-US&amp;anchor=www.earlyisgood.com&amp;index=1&amp;md5=c11543cc6525abf601ae1f9aad43d3d8\" rel=\"nofollow noopener\" shape=\"rect\">www.earlyisgood.com<\/a>.\n<\/p>\n<p>\n<b>About Social Capital<\/b>\n<\/p>\n<p>\nSocial Capital makes big bets on transformational ideas, technology, and people. Social Capital invests in smart, profit-minded opportunities and forward-thinking social investments that have the potential to shape a better future.\n<\/p>\n<p>\nTo learn more about Social Capital, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.socialcapital.com&amp;esheet=52958991&amp;newsitemid=20221102005821&amp;lan=en-US&amp;anchor=www.socialcapital.com&amp;index=2&amp;md5=1fba6fd271cfa2aeb42556c35eb011e9\" rel=\"nofollow noopener\" shape=\"rect\">www.socialcapital.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nHL Ananda 317-941-6953 <a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#111;&#x3a;&#x68;l&#x40;&#101;&#x61;&#114;&#x6c;&#121;i&#x73;&#103;&#x6f;&#111;&#x64;&#46;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x68;&#x6c;&#x40;&#x65;&#x61;&#x72;&#x6c;&#x79;&#x69;&#x73;&#x67;&#111;&#111;&#100;&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Funds will be used to complete clinical trials for new early detection test for bladder cancer INDIANAPOLIS&#8211;(BUSINESS WIRE)&#8211;#earlyisgood&#8211;Early is Good (EIG), a diagnostic solutions company focused on renal disease, announced it has closed a $4 million seed round from Social Capital, the Silicon Valley-based technology investment firm managed by Chamath Palihapitiya. EIG\u2019s mission is to &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50410","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Early Is Good Raises $4 Million Seed Round from Social Capital - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Early Is Good Raises $4 Million Seed Round from Social Capital - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Funds will be used to complete clinical trials for new early detection test for bladder cancer INDIANAPOLIS&#8211;(BUSINESS WIRE)&#8211;#earlyisgood&#8211;Early is Good (EIG), a diagnostic solutions company focused on renal disease, announced it has closed a $4 million seed round from Social Capital, the Silicon Valley-based technology investment firm managed by Chamath Palihapitiya. EIG\u2019s mission is to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-02T19:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221102005821\/en\/1622879\/21\/eig_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Early Is Good Raises $4 Million Seed Round from Social Capital\",\"datePublished\":\"2022-11-02T19:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/\"},\"wordCount\":612,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005821\\\/en\\\/1622879\\\/21\\\/eig_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/\",\"name\":\"Early Is Good Raises $4 Million Seed Round from Social Capital - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005821\\\/en\\\/1622879\\\/21\\\/eig_logo.jpg\",\"datePublished\":\"2022-11-02T19:03:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005821\\\/en\\\/1622879\\\/21\\\/eig_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005821\\\/en\\\/1622879\\\/21\\\/eig_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/early-is-good-raises-4-million-seed-round-from-social-capital\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Early Is Good Raises $4 Million Seed Round from Social Capital\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Early Is Good Raises $4 Million Seed Round from Social Capital - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/","og_locale":"en_US","og_type":"article","og_title":"Early Is Good Raises $4 Million Seed Round from Social Capital - Pharma Trend","og_description":"Funds will be used to complete clinical trials for new early detection test for bladder cancer INDIANAPOLIS&#8211;(BUSINESS WIRE)&#8211;#earlyisgood&#8211;Early is Good (EIG), a diagnostic solutions company focused on renal disease, announced it has closed a $4 million seed round from Social Capital, the Silicon Valley-based technology investment firm managed by Chamath Palihapitiya. EIG\u2019s mission is to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-02T19:03:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221102005821\/en\/1622879\/21\/eig_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Early Is Good Raises $4 Million Seed Round from Social Capital","datePublished":"2022-11-02T19:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/"},"wordCount":612,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221102005821\/en\/1622879\/21\/eig_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/","url":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/","name":"Early Is Good Raises $4 Million Seed Round from Social Capital - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221102005821\/en\/1622879\/21\/eig_logo.jpg","datePublished":"2022-11-02T19:03:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221102005821\/en\/1622879\/21\/eig_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221102005821\/en\/1622879\/21\/eig_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/early-is-good-raises-4-million-seed-round-from-social-capital\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Early Is Good Raises $4 Million Seed Round from Social Capital"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50410"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50410\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}